Quotient Clinical acquires Co-Formulate
Wednesday, December 16, 2015
Quotient Clinical, a Translational Pharmaceutics company, has acquired formulation development specialist Co-Formulate.
Quotient Clinical has brought innovation to the drug development process through its Translational Pharmaceutics platform, which challenges the conventional industry approach by integrating formulation development, real-time GMP manufacturing and clinical testing. The acquisition of Co-Formulate reinforces and extends Quotient’s existing pharmaceutical development capabilities across solid, semi-solid and liquid formulations. Co-Formulate is based adjacent to Quotient’s new GMP facility in Nottingham, U.K., which will enable seamless integration of formulation development and GMP manufacturing services.
Financial terms of the transaction were not disclosed.